Glucose Fluctuations Aggravate Myocardial Fibrosis via the Nuclear Factor-κB-Mediated Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Activation

Background Glucose fluctuations may be associated with myocardial fibrosis. This study aimed to investigate the underlying mechanisms of glucose fluctuation-related myocardial fibrosis. Methods Streptozotocin (STZ)-injected type 1 diabetic rats were randomized to five groups: the controlled blood glucose (CBG) group, uncontrolled blood glucose (UBG) group, fluctuated blood glucose (FBG) group, FBG rats injected with 0.9% sodium chloride (NaCl) (FBG + NaCl) group, and FBG rats injected with MCC950 (FBG + MCC950) group. Eight weeks later, left ventricular function was evaluated by echocardiography and myocardial fibrosis was observed by Masson trichrome staining. The primary neonatal rat cardiac fibroblasts were cultured with different concentrations of glucose in vitro. Results The left ventricular function was impaired and myocardial fibrosis was aggravated most significantly in the FBG group compared with the CBG and UBG groups. The levels of interleukin (IL)-1β, IL-18, transforming growth factor-β1 (TGF-β1), collagen type 1 (collagen I), nuclear factor (NF)-κB, and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome were significantly increased in the FBG group. In vitro, the inhibition of NF-κB and inflammasome reversed these effects. In vivo, NLRP3 inhibition with MCC950 reversed left ventricular systolic dysfunction and myocardial fibrosis induced by glucose fluctuations. Conclusion Glucose fluctuations promote diabetic myocardial fibrosis by the NF-κB-mediated inflammasome activation.

[1]  T. Lüscher,et al.  Inflammation in Metabolic Cardiomyopathy , 2021, Frontiers in Cardiovascular Medicine.

[2]  Meenakshi Sharma,et al.  Structure, Activation and Regulation of NLRP3 and AIM2 Inflammasomes , 2021, International journal of molecular sciences.

[3]  Q. Dai,et al.  Targeting HDAC6 attenuates nicotine-induced macrophage pyroptosis via NF-κB/NLRP3 pathway. , 2020, Atherosclerosis.

[4]  Jeroen J. Bax,et al.  Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging , 2020, Nature Reviews Cardiology.

[5]  L. Altucci,et al.  The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin , 2020, Cardiovascular Diabetology.

[6]  Q. Chai,et al.  Glucose fluctuations promote vascular BK channels dysfunction via PKCα/NF-κB/MuRF1 signaling. , 2020, Journal of molecular and cellular cardiology.

[7]  Y. Birnbaum,et al.  Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay , 2020, Cardiovascular Drugs and Therapy.

[8]  Zhenlian Wang,et al.  NLRP3 Inflammasome and Inflammatory Diseases , 2020, Oxidative medicine and cellular longevity.

[9]  Lu Lu,et al.  Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECs. , 2019, European journal of pharmacology.

[10]  Yi-mei Wang,et al.  Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF‐&kgr;B/p38 signaling pathway in high‐fat diet/streptozotocin‐induced diabetic mice , 2018, International immunopharmacology.

[11]  Baoping Chen,et al.  Artesunate ameliorates high glucose-induced rat glomerular mesangial cell injury by suppressing the TLR4/NF-κB/NLRP3 inflammasome pathway. , 2018, Chemico-biological interactions.

[12]  E. Latz,et al.  NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. , 2018, Circulation research.

[13]  W. Strain,et al.  Diabetes, cardiovascular disease and the microcirculation , 2018, Cardiovascular Diabetology.

[14]  Di Wang,et al.  The NLRP3 inflammasome: Role in metabolic disorders and regulation by metabolic pathways. , 2018, Cancer letters.

[15]  F. Huang,et al.  NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy , 2017, Front. Physiol..

[16]  Ting Liu,et al.  Glucose variability aggravates cardiac fibrosis by altering AKT signalling path , 2017, Diabetes & vascular disease research.

[17]  Antonio Abbate,et al.  The inflammasome in myocardial injury and cardiac remodeling. , 2015, Antioxidants & redox signaling.

[18]  T. Saikawa,et al.  Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats. , 2014, Cardiovascular research.

[19]  Yan Li,et al.  Acute Blood Glucose Fluctuation Induces Myocardial Apoptosis through Oxidative Stress and Nuclear Factor-ĸB Activation , 2012, Cardiology.

[20]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[21]  R. Carmody,et al.  NF-κB and the Transcriptional Control of Inflammation. , 2018, International review of cell and molecular biology.

[22]  T. Saikawa,et al.  Glucose Fluctuations Aggravate Cardiac Susceptibility to Ischemia/Reperfusion Injury by Modulating MicroRNAs Expression. , 2016, Circulation journal : official journal of the Japanese Circulation Society.